What is the appropriate maintenance dosing of Lokelma (sodium zirconium cyclosilicate) for a patient with serum potassium of 5.5 mEq/L?

Maintenance Lokelma Dosing for Potassium 5.5

For a patient with serum potassium of 5.5 mEq/L, start Lokelma at 10 g once daily for maintenance therapy, then titrate based on potassium monitoring. 1

Initial Approach

Since this patient has a potassium of 5.5 mEq/L (mild hyperkalemia), they do not require acute correction with three-times-daily dosing. The FDA-approved maintenance dosing strategy should be implemented directly:

• Starting dose: 10 g once daily 1
• Monitor serum potassium and adjust at intervals of 1 week or longer 1
• Titrate in 5 g increments based on response 1

Maintenance Dose Range and Titration

The recommended maintenance dose range is 5 g every other day to 15 g daily 1. This provides substantial flexibility:

• If potassium remains elevated (>5.0 mEq/L): increase to 15 g daily
• If potassium normalizes (3.5-5.0 mEq/L): continue 10 g daily
• If potassium drops below target range: decrease to 5 g daily or 5 g every other day
• If potassium becomes too low: discontinue temporarily 1

Evidence Supporting This Approach

The HARMONIZE trial demonstrated that SZC 10 g once daily maintained mean serum potassium at 4.5 mEq/L over 28 days, while 5 g daily achieved 4.8 mEq/L 2. In the long-term HARMONIZE-OLE study, 93% of patients achieved mean serum potassium ≤5.1 mEq/L across 11 months using 10 g daily as the starting maintenance dose, titrated in 5 g increments 2.

Critical Monitoring Parameters

• Assess serum potassium after 1 week of any dose adjustment 1
• Watch for hypokalemia (most common adverse effect) 2
• Monitor for edema, particularly in patients with heart failure or renal disease, as each 5 g dose contains approximately 400 mg sodium 1
• Consider increasing diuretics if edema develops 1

Important Medication Timing

Administer other oral medications at least 2 hours before or 2 hours after Lokelma to avoid binding interactions 1. This is particularly critical for medications like levothyroxine, antibiotics, and other narrow therapeutic index drugs.

Context for Chronic Management

The 2025 European guidelines emphasize that potassium binders like SZC enable continuation of life-saving RAASi therapy in patients with heart failure and chronic kidney disease 3. For a patient with potassium 5.5 mEq/L, initiating Lokelma allows optimization of disease-modifying therapies rather than downtitrating or discontinuing RAASi agents, which would worsen long-term cardiovascular and renal outcomes.

Special Populations

If this patient is on chronic hemodialysis, the approach differs:

• Start at 5 g once daily on non-dialysis days only 1
• Dose only on non-dialysis days 1
• Monitor pre-dialysis potassium after the long interdialytic interval 1